Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was 127.66B DKK, down 0.5% from the year before. Over ten years it grew 9.9% a year on average. The highest annual figure on record is 128.34B DKK in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 127.66B DKK | -0.5% |
| FY2024 | Dec 31, 2024 | 128.34B DKK | +25.1% |
| FY2023 | Dec 31, 2023 | 102.57B DKK | +37.1% |
| FY2022 | Dec 31, 2022 | 74.81B DKK | +27.6% |
| FY2021 | Dec 31, 2021 | 58.64B DKK | +8.3% |
| FY2020 | Dec 31, 2020 | 54.13B DKK | +3.1% |
| FY2019 | Dec 31, 2019 | 52.48B DKK | +11.1% |
| FY2018 | Dec 31, 2018 | 47.25B DKK | -3.5% |
| FY2017 | Dec 31, 2017 | 48.97B DKK | +1.1% |
| FY2016 | Dec 31, 2016 | 48.43B DKK | -2.0% |
| FY2015 | Dec 31, 2015 | 49.44B DKK | – |
See a number that looks wrong?